Hiroaki Mori
Impact in
- Transplantation top 10%
- Pharmacology top 10%
- Microbial Natural Products and Biosynthesis
Papers in
- Rheumatology 10
- Systemic Lupus Erythematosus Research 5
- Rheumatoid Arthritis Research and Therapies 5
- Co-authors
- Motohiro HinoTakashi FujiiFumie AbeShigetada FurukawaShigehiro TakaseYasuharu UranoKenji TakehanaEisuke Nishida
- Journals
- The Journal of Antibiotics (6 papers)Journal of Alzheimer s Disease (4 papers)Vaccine (2 papers)Journal of Nuclear Cardiology (2 papers)Biological and Pharmaceutical Bulletin (2 papers)
- Partner nations
- JapanUnited States
In The Last Decade
Hiroaki Mori
58 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 109
- Transplantation 38
- Pharmacology 151
- Molecular Biology 600
- Rheumatology 119
- Biotechnology 48
Countries citing papers authored by Hiroaki Mori
This map shows the geographic impact of Hiroaki Mori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Mori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Mori more than expected).
Fields of papers citing papers by Hiroaki Mori
This network shows the impact of papers produced by Hiroaki Mori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Mori. The network helps show where Hiroaki Mori may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroaki Mori, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 5 | |
| 5 | 2022 | 3 | |
| 6 | 2022 | 2 | |
| 7 | 2021 | 11 | |
| 8 | 2020 | 17 | |
| 9 | 2020 | 18 | |
| 10 | 2019 | 29 | |
| 11 | 2019 | 3 | |
| 12 | 2018 | 8 | |
| 13 | 2010 | 7 | |
| 14 | 2009 | 2 | |
| 15 | 2009 | 24 | |
| 16 | 2007 | 18 | |
| 17 | 2007 | 37 | |
| 18 | 2006 | 122 | |
| 19 | 2003 | 31 | |
| 20 | 2003 | 41 |
About Hiroaki Mori
Hiroaki Mori is a scholar working on Biological Psychiatry, Rheumatology, Otorhinolaryngology, Nephrology and Molecular Biology, having authored 63 papers that have together received 1.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (13 papers), Peptidase Inhibition and Analysis (6 papers), Systemic Lupus Erythematosus Research (5 papers), Alzheimer's disease research and treatments (5 papers), Protein Hydrolysis and Bioactive Peptides (5 papers), Signaling Pathways in Disease (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers). The work is most often cited by research in Transplantation (38 citations), Pharmacology (151 citations), Molecular Biology (600 citations), Rheumatology (119 citations) and Biotechnology (48 citations). Hiroaki Mori has collaborated with scholars based in Japan and United States. Frequent co-authors include Motohiro Hino, Takashi Fujii, Fumie Abe, Shigetada Furukawa, Shigehiro Takase, Yasuharu Urano, Kenji Takehana, Eisuke Nishida, Satoshi Matsuda and Shigeo Koyasu. Their work appears in journals such as The Journal of Antibiotics, Journal of Alzheimer s Disease, Vaccine, Journal of Nuclear Cardiology and Biological and Pharmaceutical Bulletin.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.